Financial Performance - Total net sales for the three months ended June 30, 2023, were $291.6 million, representing a 10.6% increase from $263.6 million in the same period of 2022[130] - Total net sales for the six months ended June 30, 2023, reached $568.3 million, a 15.0% increase from $494.2 million in 2022[143] - Net sales in the United States increased by $20.2 million, or 9.0%, primarily due to increased spine product sales and enabling technologies[130] - Net sales in the United States increased by $57.9 million (13.7%) primarily due to higher spine product sales, including robotic spine instruments[143] - International net sales rose by $7.8 million, or 20.2%, driven by increased spine product sales in existing territories[130] - International net sales rose by $16.2 million (22.3%), driven by increased spine product sales in existing territories[144] Costs and Expenses - Cost of goods sold for the three months ended June 30, 2023, was $76.5 million, an increase of 11.7% from $68.5 million in 2022, representing 26.2% of net sales[132] - Cost of goods sold for the six months ended June 30, 2023, was $147.3 million, reflecting a 15.4% increase from $127.6 million in 2022[145] - Research and development expenses increased by $4.0 million, or 22.7%, totaling $21.3 million, which is 7.3% of net sales[133] - Research and development expenses increased by $7.6 million (21.9%) to $42.4 million, representing 7.5% of net sales[146] - Selling, general and administrative expenses rose by $13.4 million, or 12.5%, totaling $120.1 million, which is 41.2% of net sales[134] - Selling, general and administrative expenses rose by $35.0 million (16.9%) to $242.5 million, accounting for 42.7% of net sales[148] Income and Tax - Other income increased by $5.7 million, or 206.2%, reaching $8.5 million, primarily due to higher interest income from marketable securities[139] - Other income increased significantly by $10.0 million (192.3%) to $15.2 million, primarily due to higher interest income from marketable securities[152] - The income tax provision for the three months ended June 30, 2023, was $17.0 million, a 6.3% increase from $15.9 million in 2022, with an effective tax rate of 22.7%[140] Cash Flow and Investments - The net cash provided by operating activities for the six months ended June 30, 2023, was $88.3 million, an increase of $6.8 million from $81.6 million in 2022[156] - Cash used in investing activities increased significantly to $63.2 million from $13.2 million, reflecting net inflows from marketable securities[158] - The company expects to continue investing in surgical sets and expanding its U.S. sales force while exploring potential future acquisitions[155] Strategic Outlook - The company expects the merger with NuVasive to close in the third quarter of 2023, pending regulatory approvals[116] - The company emphasizes the importance of compliance with applicable laws and regulations affecting its business operations[166] - The company highlights its ability to safeguard intellectual property and defend against legal proceedings[166] - Trends in the medical device industry and general economic conditions are noted as significant factors impacting the business[166] - The company acknowledges the evolving environment and the emergence of new risk factors and uncertainties[166] - Forward-looking statements in the quarterly report are only valid as of the report date, with no obligation to update them[167]

Globus Medical, Inc. (NYSE:GMED) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Kearns - Senior Vice President of Business Development and Investor Relations Dan Scavilla - President and CEO Keith Pfeil - Senior Vice President and Chief Financial Officer Conference Call Participants Mike Miksic - Barclays Shagun Singh - RBC David Saxon - Needham & Co Sam Dane - BTIG Kyle Rose - Canaccord Vik Chopra - Wells Fargo Operator Welcome to Globus Medical’s First Quarter 2023 Earn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 04-3744954 (State or oth ...

Globus Medical, Inc. (NYSE:GMED) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Brian Kearns - Senior Vice President of Business Development and Investor Relations Dan Scavilla - President and CEO Keith Pfeil - Senior Vice President and Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Matt Taylor - Jefferies Matt Miksic - Barclays Vik Chopra - Wells Fargo David Saxon - Needham and Company Steve Lichtman - Oppenheimer Matthew O'Brien ...

International Sales and Market Presence - In the year ended December 31, 2022, international sales accounted for approximately 14.8% of total sales[19] - As of December 31, 2022, Globus had a direct or distributor sales presence in 53 countries outside the United States[35] - The company expects to continue expanding its international presence through the commercialization of additional products[20] - International operations account for approximately 14.8% of total net sales, with significant revenues generated in Japan, the Euro zone, United Kingdom, and Australia[185] Product Development and Innovation - Globus launched 8 new products in 2022 and has a range of new products in various stages of development[20] - Globus has introduced over 230 products designed for the treatment of musculoskeletal disorders since its inception[22] - The ExcelsiusGPS platform, a robotic guidance and navigation system, supports minimally invasive and open procedures[30] - The company employs an integrated team approach to product development, allowing for rapid product conception to launch[32] - The company has launched the Excelsius3D™ imaging system and continues to introduce new products related to the ExcelsiusGPS platform and orthopedic trauma products, but faces challenges in convincing surgeons and hospitals of their merits[119] Regulatory Compliance and Risks - The company is subject to extensive FDA regulations, requiring pre-market clearance or approval for medical devices, which can impact time to market[57] - The company has received a warning letter from the FDA regarding non-conformities related to human tissue products, which remains open as of December 31, 2022[64] - The company must comply with the EU Medical Device Regulation (MDR) by May 2027, which includes stricter technical documentation requirements[67] - The company is subject to extensive governmental regulations, including the FDA's good manufacturing practice regulations, which could impact operations[91] - The company must comply with international laws and regulations to market products outside the U.S., with potential adverse actions from foreign regulatory bodies if standards are not met[156] - Non-compliance with FDA regulations could result in sanctions such as fines, recalls, or even criminal penalties, adversely affecting the company's reputation and financial condition[147] Financial Performance and Growth Strategies - Net sales increased to $1,022.8 million in 2022, reflecting rapid growth since inception[187] - The company anticipates substantial increases in operating expenses to support growth strategies, including adding sales representatives and conducting clinical trials[186] - Future growth will depend on the success of growth strategies, brand strength, and market success of current and future products[188] - The existing revolving credit facility contains restrictive covenants that may limit operational flexibility and ability to engage in certain transactions[194] Supply Chain and Manufacturing - The company has expanded its in-house manufacturing capabilities, with significant portions of implant products manufactured in Pennsylvania and regenerative biologics processed in Texas[41] - The company maintains a small number of carefully selected suppliers for key products to ensure reliability and quality compliance[43] - The company relies on less than five third-party suppliers for allograft implants and products, which poses risks related to pricing, availability, quality, and delivery schedules[162] Competition and Market Challenges - The musculoskeletal devices industry is facing intense competition, with established companies increasing pricing pressure due to new entrants and technologies[95] - Surgeons and hospitals are critical in the adoption of new products, and their acceptance depends on education regarding the benefits and safety of the products[92] - The proliferation of physician-owned distributorships (PODs) may increase pricing pressure and impact the company's ability to compete effectively[113] Management and Organizational Structure - The company is highly dependent on key members of senior management, particularly Executive Chairman David C. Paul and CEO Daniel T. Scavilla, and their loss could disrupt operations and strategic plans[115] - As of December 31, 2022, executive officers and directors beneficially owned approximately 74.5% of the voting power of the outstanding capital stock[207] - David C. Paul, the Executive Chairman, controlled approximately 22.4% of the Class A and Class B common stock, representing about 74.3% of the voting power[208] Legal and Liability Risks - The company faces potential product liability claims due to the inherent risks in the medical device industry, which could result in significant financial liabilities[204] - Product liability claims could increase insurance costs or lead to inadequate coverage, adversely affecting the company's financial condition[206] - The company faces scrutiny under healthcare fraud and abuse laws, which could result in criminal and civil sanctions if violated[167] Economic and Market Conditions - Negative trends in the general economy, including inflation and financial market volatility, may adversely affect business performance[190] - The company faces risks from currency exchange rate fluctuations that could adversely affect profitability due to international operations[185] Intellectual Property and Patent Issues - As of December 31, 2022, the company owned 1,527 issued U.S. patents and had applications pending for 518 U.S. patents, indicating a strong intellectual property portfolio[46] - The company relies on patent, copyright, and trademark laws to protect proprietary technologies, but faces uncertainties regarding the effectiveness of these protections[195] - The medical device industry is characterized by patent litigation, which could divert management's attention and incur substantial costs[199]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of exchange on which registered Cl ...

Globus Medical, Inc. (NYSE:GMED) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development & IR Daniel Scavilla - President, CEO & Director Keith Pfeil - SVP & CFO Conference Call Participants Shagun Chadha - RBC Capital Markets Vikramjeet Chopra - Wells Fargo Securities Richard Newitter - Truist Securities David Saxon - Needham & Company Jason Wittes - Loop Capital Markets Craig Bijou - Bank of America Merrill Lynch Andrew Ranieri - Morgan Stan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...

Globus Medical, Inc. (NYSE:GMED) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Brian Kearns - Senior Vice President, Business Development & Investor Relations Dan Scavilla - President & Chief Executive Officer Keith Pfeil - Senior Vice President & Chief Financial Officer Conference Call Participants Shagun Singh - RBC Capital Markets Matthew O'Brien - Piper Sandler David Saxon - Needham and Company Kyle Rose - Canaccord Jason Wittes - Loop Capital Richard Newitter - Truist V ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...